Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 11, 2026 | June 15, 2026 |
| CervoMed Inc.DFFN · Entity 7338 | Director | July 01, 2021 | July 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 79,565 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 15,294 · Balance 79,565 F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $8.50 · Expires 2036-06-11 | Direct | 33,540 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 33,540 · Balance 33,540 F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
CervoMed Inc.
Report date July 01, 2021 · Filed July 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2031-07-01 | Direct | 83,300 |
Reported balance
After 2021-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-01 · Grant · Acquired 83,300 · Balance 83,300 F1: The shares underlying the options will vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a 12-month period beginning July 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the options will vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a 12-month period beginning July 1, 2021.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACETO CORP
Report date October 01, 2019 · Filed October 03, 2019
Section 16 reporting ended · disclosed 2019-10-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-10-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-10-01 · Other · Disposed 18,248 · Balance 0 F1: On February 19, 2019, the Issuer and certain of its U.S. subsidiaries (collectively, the "Debtors") each filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of New Jersey (the "Bankruptcy Court"). On September 18, 2019, the Issuer's Second Modified Joint Plan of Liquidation of Aceto Corporation and Its Affiliated Debtors (as amended and supplemented, the "Plan") was confirmed by the Bankruptcy Court. As of October 1, 2019 at 12:01 a.m. (Eastern Standard Time), all applicable conditions set forth in the Plan were satisfied or waived and the effective date of the Plan occurred (the "Effective Date"). F2: Pursuant to the Plan, all existing equity interests were cancelled on the Effective Date; provided that one share of the Issuer's common stock was issued and transferred to the Plan Administrator (as defined in the Plan) for purposes of administering the wind-down of the Issuer. Accordingly, this Form 4 shall constitute an exit filing for the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 19, 2019, the Issuer and certain of its U.S. subsidiaries (collectively, the "Debtors") each filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of New Jersey (the "Bankruptcy Court"). On September 18, 2019, the Issuer's Second Modified Joint Plan of Liquidation of Aceto Corporation and Its Affiliated Debtors (as amended and supplemented, the "Plan") was confirmed by the Bankruptcy Court. As of October 1, 2019 at 12:01 a.m. (Eastern Standard Time), all applicable conditions set forth in the Plan were satisfied or waived and the effective date of the Plan occurred (the "Effective Date").
F2: Pursuant to the Plan, all existing equity interests were cancelled on the Effective Date; provided that one share of the Issuer's common stock was issued and transferred to the Plan Administrator (as defined in the Plan) for purposes of administering the wind-down of the Issuer. Accordingly, this Form 4 shall constitute an exit filing for the Reporting Person.
PFIZER INC
Report date September 14, 2007 · Filed September 17, 2007
Section 16 reporting ended · disclosed 2007-09-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 66,887 |
Reported balance
After 2007-09-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2007-09-14 · Grant · Acquired 345 · Balance 66,887 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 20:29 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 33,540 | $0.00 Strike: $8.50 | $0.00 |
DisclosureSEC source: 0000882796-26-000052 · form4.xml · derivative · entry 2 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,540 Underlying: Common Stock · 33,540 shares Expires 2036-06-11 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:29 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 15,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000882796-26-000052 · form4.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,565 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 27,181 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001171843-25-003915 · ownership.xml · derivative · entry 2 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,181 Underlying: Common Stock · 27,181 shares Expires 2035-06-12 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003915 · ownership.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,271 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:28 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 49,933 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001127602-24-018725 · form4.xml · derivative · entry 2 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,933 Underlying: Common Stock · 49,933 shares Expires 2034-06-12 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:28 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 6,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018725 · form4.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,771 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 30, 2024 Filed May 31, 2024 20:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 7,861 | $6.36 | $49,995.96 |
DisclosureSEC source: 0001127602-24-017121 · form4.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,951 Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 39,072 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0001127602-23-018793 · form4.xml · derivative · entry 2 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,072 Underlying: Common Stock · 39,072 shares Expires 2033-06-13 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 16,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018793 · form4.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,090 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:34 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,360 | $8.27 | $11,247.20 |
DisclosureSEC source: 0001127602-23-017556 · form4.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,345 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $11,250. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:37 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,271 | $8.85 | $11,248.35 |
DisclosureSEC source: 0001127602-23-008381 · form4.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,985 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $11,250. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 23:26 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 842 | $13.36 | $11,249.12 |
DisclosureSEC source: 0001127602-22-026825 · form4.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,714 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $11,250. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 20:34 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 809 | $13.90 | $11,245.10 |
DisclosureSEC source: 0001127602-22-022014 · form4.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,872 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $11,250. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:41 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,022 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001127602-22-017148 · form4.xml · derivative · entry 2 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,022 Underlying: Common Stock · 30,022 shares Expires 2032-06-07 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:41 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017148 · form4.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,063 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:37 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,138 | $9.31 | $10,594.78 |
DisclosureSEC source: 0001127602-22-016395 · form4.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,197 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $11,250, prorated to $10,597.83 based on the increase in the annual retainer fee effective April 18, 2022. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 602 | $16.61 | $9,999.22 |
DisclosureSEC source: 0001127602-22-007730 · form4.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,059 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 829 | $12.06 | $9,997.74 |
DisclosureSEC source: 0001127602-21-030059 · form4.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,457 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:36 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 628 | $15.92 | $9,997.76 |
DisclosureSEC source: 0001127602-21-024778 · form4.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| July 01, 2021 Filed Jul 7, 2021 01:42 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 83,300 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001437749-21-016511 · rdgdoc.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,300 Underlying: Common Stock · 83,300 shares Expires 2031-07-01 F1 · derivative.exercise_date: The shares underlying the options will vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a 12-month period beginning July 1, 2021. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:39 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0001127602-21-018189 · form4.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-05-25 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:52 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 61,300 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001437749-20-013420 · rdgdoc.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,300 Underlying: Common Stock · 61,300 shares Expires 2030-06-17 F1 · derivative.exercise_date: The shares underlying the options vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a one-year period beginning on June 17, 2020. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:33 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001127602-20-016580 · form4.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-05-12 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 22:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantNon-Qualified Stock Option · Derivative | 15,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001127602-20-009112 · form4.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-02-27 F1 · shares: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 18:02 UTC | ACETO CORP ACETQ · Entity 154617 | OtherCOMMON STOCK | 18,248 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-19-000830 · ownership.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On February 19, 2019, the Issuer and certain of its U.S. subsidiaries (collectively, the "Debtors") each filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of New Jersey (the "Bankruptcy Court"). On September 18, 2019, the Issuer's Second Modified Joint Plan of Liquidation of Aceto Corporation and Its Affiliated Debtors (as amended and supplemented, the "Plan") was confirmed by the Bankruptcy Court. As of October 1, 2019 at 12:01 a.m. (Eastern Standard Time), all applicable conditions set forth in the Plan were satisfied or waived and the effective date of the Plan occurred (the "Effective Date"). F2 · shares: Pursuant to the Plan, all existing equity interests were cancelled on the Effective Date; provided that one share of the Issuer's common stock was issued and transferred to the Plan Administrator (as defined in the Plan) for purposes of administering the wind-down of the Issuer. Accordingly, this Form 4 shall constitute an exit filing for the Reporting Person. F2 · price: Pursuant to the Plan, all existing equity interests were cancelled on the Effective Date; provided that one share of the Issuer's common stock was issued and transferred to the Plan Administrator (as defined in the Plan) for purposes of administering the wind-down of the Issuer. Accordingly, this Form 4 shall constitute an exit filing for the Reporting Person. F2 · balance_after: Pursuant to the Plan, all existing equity interests were cancelled on the Effective Date; provided that one share of the Issuer's common stock was issued and transferred to the Plan Administrator (as defined in the Plan) for purposes of administering the wind-down of the Issuer. Accordingly, this Form 4 shall constitute an exit filing for the Reporting Person. Read SEC document |
| June 13, 2019 Filed Jul 19, 2019 19:00 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 13,100 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001437749-19-014278 · rdgdoc.xml · derivative · entry 2 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,100 Underlying: Common Stock · 13,100 shares Expires 2029-06-13 F1 · derivative.exercise_date: The shares underlying the options vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a one-year period beginning on June 13, 2019. Read SEC document |
| June 13, 2019 Filed Aug 6, 2019 12:53 UTC Amendment | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 19,200 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001437749-19-015539 · rdgdoc.xml · derivative · entry 2 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 Underlying: Common Stock · 19,200 shares Expires 2029-06-13 F1 · derivative.exercise_date: The shares underlying the options vest in equal parts on the last calendar day of each month until fully vested on May 31, 2020. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:37 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001437749-18-012013 · rdgdoc.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: The shares underlying the options vest in 12 equal (or as nearly equal as possible) monthly installments over a one-year period beginning on the grant date, provided that the final tranche will vest on the day immediately prior to the subsequent annual meeting. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:02 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-18-000261 · rdgdoc.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-01-02 F1 · derivative.exercise_date: The shares underlying the options vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a one-year period beginning on January 31, 2018. Read SEC document |
| December 07, 2017 Filed Dec 11, 2017 10:20 UTC | ACETO CORP ACET · Entity 154617 | GrantCOMMON STOCK | 6,737 | $10.39 | $69,997.43 |
DisclosureSEC source: 0001140361-17-045562 · doc1.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,248 F1 · shares: Grant of restricted stock pursuant to long term incentive plan; vests 100% after 13 months. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 21:29 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 23,900 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001437749-17-011435 · rdgdoc.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2027-06-15 F1 · derivative.exercise_date: The shares underlying the options vest in equal parts on the fifteenth day of each month until fully vested on June 15, 2018. Read SEC document |
| December 08, 2016 Filed Dec 13, 2016 21:26 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001437749-16-043293 · rdgdoc.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2026-12-08 F1 · derivative.exercise_date: The shares underlying the options vest in equal parts on the last calendar day of each month until fully vested on November 30, 2019. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 16:01 UTC | ACETO CORP ACET · Entity 154617 | GrantCOMMON STOCK | 3,467 | $20.19 | $69,998.73 |
DisclosureSEC source: 0001140361-16-088599 · doc1.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,511 F1 · shares: Restricted Stock vests 100% after 13 months. Read SEC document |
| September 14, 2007 Filed Sep 17, 2007 22:02 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 345 | $24.29 | $8,380.05 |
DisclosureSEC source: 0000078003-07-000237 · lev1584.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,887 Underlying: Common Stock · 345 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2007 Filed Sep 4, 2007 17:54 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 295 | $24.84 | $7,327.80 |
DisclosureSEC source: 0000078003-07-000222 · lev1574.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,542 Underlying: Common Stock · 295 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2007 Filed Aug 17, 2007 12:54 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 1,139 | $23.53 | $26,800.67 |
DisclosureSEC source: 0000078003-07-000209 · lev1565.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,247 Underlying: Common Stock · 1,139 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 31, 2007 Filed Aug 1, 2007 21:20 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 365 | $23.51 | $8,581.15 |
DisclosureSEC source: 0000078003-07-000187 · lev1556.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,108 Underlying: Common Stock · 365 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 13, 2007 Filed Jul 17, 2007 14:47 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 327 | $25.91 | $8,472.57 |
DisclosureSEC source: 0000078003-07-000176 · lev1547.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,743 Underlying: Common Stock · 327 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 29, 2007 Filed Jul 3, 2007 14:45 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 330 | $25.57 | $8,438.10 |
DisclosureSEC source: 0000078003-07-000166 · lev1535.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,416 Underlying: Common Stock · 330 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2007 Filed Jun 18, 2007 20:38 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 323 | $26.47 | $8,549.81 |
DisclosureSEC source: 0000078003-07-000139 · lev1526.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,086 Underlying: Common Stock · 323 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 31, 2007 Filed Jun 1, 2007 18:36 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 297 | $27.49 | $8,164.53 |
DisclosureSEC source: 0000078003-07-000128 · lev1516.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,763 Underlying: Common Stock · 297 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2007 Filed May 16, 2007 19:54 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 969 | $27.10 | $26,259.90 |
DisclosureSEC source: 0000078003-07-000118 · lev1507.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,466 Underlying: Common Stock · 969 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 08, 2007 Filed May 8, 2007 19:48 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 14,210 | $27.34 | $388,501.40 |
DisclosureSEC source: 0000078003-07-000109 · lev1501.xml · nonDerivative · entry 4 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,061 Read SEC document |
| May 07, 2007 Filed May 8, 2007 19:48 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $18.35 | $0.00 |
DisclosureSEC source: 0000078003-07-000109 · lev1501.xml · derivative · entry 6 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2007-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option became exercisable in 5 equal annual installments beginning on August 28,1998. Read SEC document |
| May 07, 2007 Filed May 8, 2007 19:48 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 57,386 | $27.12 | $1,556,308.32 |
DisclosureSEC source: 0000078003-07-000109 · lev1501.xml · nonDerivative · entry 3 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,271 Read SEC document |
| May 07, 2007 Filed May 8, 2007 19:48 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 84,552 | $26.96 | $2,279,521.92 |
DisclosureSEC source: 0000078003-07-000109 · lev1501.xml · nonDerivative · entry 2 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,657 Read SEC document |
| May 07, 2007 Filed May 8, 2007 19:48 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 90,000 | $18.35 | $1,651,500.00 |
DisclosureSEC source: 0000078003-07-000109 · lev1501.xml · nonDerivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2007 Filed May 1, 2007 20:41 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 318 | $26.46 | $8,414.28 |
DisclosureSEC source: 0000078003-07-000098 · lev1496.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,497 Underlying: Common Stock · 318 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 13, 2007 Filed Apr 17, 2007 15:22 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 303 | $26.67 | $8,081.01 |
DisclosureSEC source: 0000078003-07-000071 · lev1474.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,179 Underlying: Common Stock · 303 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 30, 2007 Filed Apr 3, 2007 15:29 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 315 | $25.26 | $7,956.90 |
DisclosureSEC source: 0000078003-07-000062 · lev1460.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,876 Underlying: Common Stock · 315 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.